Enzyme Inhibitor Combined with Chemotherapy Delays Glioblastoma Growth
This combination therapy, tested preclinically, could potentially improve patient outcomes.
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.
The regression seen in this combination therapy of temozolomide and the inhibitor SLC-0111 — which targets the enzyme carbonic anhydrase 9, or CA9 — was greater than that seen with either SLC-0111 or temozolomide alone, says research leader Anita Hjelmeland, Ph.D., assistant professor in the Department of Cell, Developmental and Integrative Biology at the University of Alabama at Birmingham.
“Our experiments strongly suggest that a strategy to target a carbonic anhydrase that is increased in glioblastoma, CA9, will improve temozolomide efficacy,” Hjelmeland said. “We believe the drug combination could improve patient outcomes in glioblastomas sensitive to chemotherapy.”
Click here to read more.
NeuroSafe 2019 Symposium
Aug. 8-9, 2019; Minneapolis
SNSA Congress 2019
Aug. 8-11, 2019; Cape Town, South Africa
2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.
2019 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 28-31, 2019; Orlando, Fla.
Sept. 8-11, 2019; Leuven, Belgium